Method for diagnosis of primary hyperaldosteronism
AssigneeAttoquant Diagnostics GmbH
InventorsMarko Poglitsch, Cornelia Schwager, Dunja Van Oyen, Martin Leitner
Life of this patent
Estimating the term…
Abstract
Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.
Claims28
A method for indicating primary hyperaldosteronism (PHA) in a human subject, comprising:
- incubating a blood sample or blood derived sample ex vivo until a steady state equilibrium is reached for angiotensin II, in which the actual overall degradation rate of angiotensin II is equal to the actual overall formation rate of angiotensin II;
- measuring an aldosterone level and the angiotensin II (Ang II) level in the same sample from the human subject;
- and
- calculating a ratio between the aldosterone level and the Ang II level (aldosterone-to-angiotensin II-ratio, AA2R), wherein an AA2R which is higher than an AA2R of one or more confirmed non-PHA human subjects indicates primary hyperaldosteronism and/or an AA2R which is lower than an AA2R of one or more confirmed PHA human subjects indicates no primary hyperaldosteronism.
A method for obtaining an aldosterone-to-angiotensin II-ratio (AA2R), comprising:
- measuring an aldosterone level and an angiotensin II (Ang II) level in a blood sample or blood derived sample from a human subject wherein:
- the sample is incubated ex vivo until a steady state equilibrium is reached for angiotensin II, in which the actual overall degradation rate of angiotensin II is equal to the actual overall formation rate of angiotensin II;
- said steady state equilibrium is conserved by adding at least one protease inhibitor;
- and/or at least one chaotropic agent;
- and/or by denaturation by heat, salt, pH or detergent;
- and/or by cooling;
- and
- the angiotensin II level is measured in the steady state equilibrium;
- and
- calculating a ratio between the aldosterone level and the Ang II level (aldosterone-to-angiotensin II-ratio, AA2R).
Dependencies are inferred from the claim text.